New cGMP facility starting operational production in Q4-2019
HALIX meets aggressive timelines for new manufacturing facility
Leiden, the Netherlands, August 9th 2019 – HALIX, a contract development and manufacturing organization of clinical and commercial proteins and viral products, based in the Netherlands, announced today that they have met their major milestone with the interim delivery of their new 6,700 m2 cGMP facility in Leiden Bio Science Park.
Following one year of construction, HALIX has completed its new state-of-the-art cGMP facility for the development and production of biopharmaceutical drug substances.
The new five-level production facility contains a state-of-the-art manufacturing line for viral vaccines and viral vectors and a separate protein manufacturing area with a capacity up to 1,000 Liter single-use bioreactors. In addition, lab space is available for process development, analytical development and quality control. All cleanroom areas have a unidirectional process flow and are designed to allow commercial manufacturing of biopharmaceutical products.
“This new facility offers our current and future clients capacity and flexibility for future expansion and will allow for cGMP manufacturing solutions for viral products, proteins, gene therapy and client-specific new technologies,” said Roland Hecht, HALIX Chief Customer Officer.
Alex Huybens, HALIX Chief Operations Officer, further added “We are very pleased to have met this major milestone for our new manufacturing facility. We have made great progress under very aggressive timelines. After a construction time of just 12 months, we are now able to start the production of viral products and protein production will follow soon. This milestone aligns with our growth and expansion strategy that will enable us to accommodate the growing market demand as well as our clients’ demands”.
About HALIX
HALIX B.V. is a biopharmaceutical contract development and manufacturing organization (CDMO) for biologics enabling the treatment and prevention of life threatening diseases. The company is focused on mammalian expression systems for the production of viral vectors and recombinant proteins. HALIX leverages scalable single-use, state-of-the-art bioprocessing technologies to provide its customers with services for the development and GMP manufacturing of drug substance and drug product. HALIX has entered into a number of contracts for the production of oncolytic immunotherapies and vaccines, utilizing innovative technologies. The company opened its state-of-the-art 6,700 m2 GMP manufacturing facility in 2019, offering 1,000L SUB capacities, at the Leiden Bio Science Park, the Netherlands. HALIX belongs to the family owned Droege Group AG. More information is available on: www.halix.nl
About Droege Group
Droege Group (founded in 1988) is an independent advisory and investment company under full family ownership. The company acts as a specialist for tailor-made transformation programs aiming to enhance corporate value. Droege Group combines its corporate family-run structure and capital strength into a family-equity business model. The group carries out direct investments with its own equity in corporate spin-offs and medium-sized companies in “special situations”. With the guiding principle “execution – following the rules of art”, the group is a pioneer in execution-oriented corporate development. Droege Group follows a focused investment strategy based on current megatrends (knowledge, connectivity, prevention, demography, specialization, future work, shopping 4.0). Enthusiasm for quality, innovation and speed determines the company’s actions. In recent years Droege Group has successfully positioned itself in domestic and international markets and operates in 30 countries. More information is available on: www.droege-group.com
Contact
Corporate Communications HALIX B.V.
Tel. + 31 (0)88 1959000
Email: communications@halix.nl